Genialis Presents Data at SITC 2023 on RNA-Based Biomarkers to Predict Immunotherapy Response

Our portfolio company , Genialis, the RNA-biomarker company,  announced new data detailing how RNA sequencing data can help elucidate tumor biologies that may be amenable to immunotherapies and targeted agents. The information was presented in two posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

Genialis found the Xerna™ TME Panel, an RNA-based pan-tumor biomarker previously shown to be predictive of responses to multiple immune-targeted cancer therapies and  introduced its ResponderID MSI program, demonstrating how a machine learning-based classifier of microsatellite instability (MSI) from RNA sequencing data performs comparably to state of the art IHC- and PCR-based MSI detection methods.

Access to their full press release here